Cisplatin enriched CSCs derived from HeLa cells.

<p><b>A:</b> The workflow of HeLa-CSC enrichment and isolation. B-C: Tumor development in response to various dose of cisplatin administrated every 3 days. The quantification of tumor volume (B) and representative image (C) were shown. n = 3 for each group, and * indicates p<0.01 compared to control group. D-E: The morphology (D) and expression of surface markers CD133 and CD49f according to flow cytometry (E) in isolated HeLa-CSCs. F-G: Expression levels of classic stem cell markers in HeLa-CSCs as measured by qPCR (F). n = 3 for each group, and * indicates p<0.01. Expression of 4 markers was confirmed by immunofluorescence staining (G).